acquired IPR&D

The cost of research and development projects acquired through business combinations that have not yet reached technological feasibility.

Acquired In-Process Research and Development (IPR&D) represents the value assigned to ongoing research and development projects of an acquired company that have not yet reached technological feasibility and have no alternative future use. Under accounting standards, when one company buys another, it must allocate the purchase price to all identifiable assets. The portion allocated to these incomplete, high-risk R&D pipelines is classified as acquired IPR&D. For investors, this line item is highly significant because of its immediate impact on profitability. Under GAAP, these acquired projects must often be expensed immediately in the quarter the acquisition closes, rather than capitalized on the balance sheet and amortized over time. This accounting treatment can cause a massive, one-time plunge in GAAP operating income and net income, making a highly profitable acquirer look temporarily unprofitable. To assess core operational performance, many companies exclude these charges from their "adjusted" or non-GAAP earnings metrics. However, retail investors should exercise caution. While these are technically non-cash accounting charges at the moment of the write-off, they represent real cash spent to buy the pipeline. Routinely ignoring acquired IPR&D can lead to an overestimation of an acquisitive company's true capital efficiency and return on investment.

Company A acquires a clinical-stage biotech firm for $500 million in cash. During the purchase price allocation, appraisers determine that $300 million of the purchase price is directly attributable to an experimental oncology drug in Phase II trials. Because the drug has not yet received regulatory approval and has no alternative use, Company A must record a $300 million acquired IPR&D expense in its current-quarter income statement, reducing its GAAP net income by $300 million.